A Clinton Twist On Price Negotiation: Hillary’s Role With PEPFAR
Former President Bill Clinton's convention speech cites his wife's experience with driving down cost of HIV therapy supported by the AIDS relief program.
You may also be interested in...
The presidential campaign is about to begin in earnest, and for biopharma companies, the biggest question is what the outcome will mean for the pricing climate in the US. It isn’t an easy question to answer.
Multiple simultaneous sponsors, foreshortened regulatory reviews, and a packet of unanswered post-approval efficacy issues make for what should be very competitive – and inherently comparative – post-market assessment period for the upcoming SARS-CoV-2 vaccines.
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.